Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026

Key Takeaways

• Phase II AK112‑206 trial shows 70.8% ORR in MSS mCRC patients
• 20 mg/kg dose yields 79.1% 9‑month response durability vs 41.5% at 10 mg/kg
• Serious treatment‑related adverse events occurred in 20.4% of participants
• HARMONi‑GI3 Phase III will compare ivonescimab + FOLFOX vs bevacizumab + FOLFOX
• Ivonescimab combines PD‑1 blockade and VEGF inhibition in a single bispecific molecule

Pulse Analysis

Metastatic colorectal cancer (mCRC) remains a therapeutic challenge, especially for the 95% of patients whose tumors are microsatellite stable (MSS) and therefore unresponsive to conventional checkpoint inhibitors. The disease’s immune‑cold microenvironment drives reliance on chemotherapy and anti‑VEGF agents, yet durability of response is limited. Ivonescimab’s bispecific design—simultaneously blocking PD‑1 and neutralizing VEGF—aims to remodel the tumor microenvironment, enhancing immune infiltration while curbing angiogenesis, a strategy that could fill a critical gap in MSS mCRC treatment.

The ASCO‑presented AK112‑206 interim data provide early validation of this concept. Among 49 treatment‑naïve patients receiving ivonescimab with mFOLFOX6, the overall response rate reached 70.8% and disease control was universal. Notably, the 20 mg/kg cohort achieved a 79.1% nine‑month response durability, markedly higher than the 41.5% observed at 10 mg/kg, indicating a dose‑response relationship. Safety was comparable to standard regimens, with serious treatment‑related adverse events in only 20.4% and no new signals, suggesting the bispecific’s tolerability aligns with existing first‑line options.

Looking ahead, Summit’s HARMONi‑GI3 Phase III trial will pit ivonescimab + FOLFOX against the current bevacizumab + FOLFOX standard, a pivotal head‑to‑head comparison that could redefine first‑line therapy for MSS mCRC. If the trial confirms superior efficacy and comparable safety, ivonescimab could capture a sizable share of the $5 billion global mCRC market, attract partnership interest, and accelerate regulatory pathways in the U.S. and Europe. The drug’s unique mechanism also positions it for expansion into other solid tumors where dual PD‑1/VEGF inhibition may yield synergistic benefits.